FLT3 Inhibitors in AML

被引：0
|
作者：
Stone, R. M. [1 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Adult Leukemia Program, Boston, MA 02115 USA
来源：
ANNALS OF HEMATOLOGY | 2015年 / 94卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：101 / 102
页数：2
相关论文
共 50 条
  • [41] Which FLT3 Inhibitor for Treatment of AML?
    Senapati, Jayastu
    Kadia, Tapan Mahendra
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (03) : 359 - 380
  • [42] Which FLT3 Inhibitor for Treatment of AML?
    Jayastu Senapati
    Tapan Mahendra Kadia
    Current Treatment Options in Oncology, 2022, 23 : 359 - 380
  • [43] The Future of Targeting FLT3 Activation in AML
    Leick, Mark B.
    Levis, Mark J.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (03) : 153 - 167
  • [44] Prognostic relevance of FLT3 mutations in AML
    Blau, O.
    Berenstein, R.
    Sindarm, A.
    Baldus, C. D.
    Blau, I. W.
    ONKOLOGIE, 2011, 34 : 77 - 77
  • [45] The Future of Targeting FLT3 Activation in AML
    Mark B. Leick
    Mark J. Levis
    Current Hematologic Malignancy Reports, 2017, 12 : 153 - 167
  • [46] Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
    Nicholas J. Short
    Daniel Nguyen
    Farhad Ravandi
    Blood Cancer Journal, 13
  • [47] The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors
    Hunter, HM
    Pallis, M
    Seedhouse, CH
    Grundy, M
    Gray, C
    Russell, NH
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (01) : 26 - 33
  • [48] FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML
    Matsukawa, Toshihiro
    Onozawa, Masahiro
    Kondo, Takeshi
    Kanaya, Minoru
    Hidaka, Daisuke
    Ota, Shuichi
    Mori, Akio
    Shigematsu, Akio
    Miyagishima, Takuto
    Kakinoki, Yasutaka
    Hashiguchi, Junichi
    Yamamoto, Satoshi
    Yamamoto, Masayo
    Wakasa, Kentaro
    Takahata, Mutsumi
    Ishihara, Toshimichi
    Haseyama, Yoshihito
    Fujimi, Akihito
    Igarashi, Tetsuya
    Sarashina, Takehiro
    Iyama, Satoshi
    Kobayashi, Ryoji
    Sakai, Hajime
    Fujimoto, Katsuya
    Inamura, Junki
    Kanisawa, Yuji
    Hirabayashi, Shinsuke
    Endo, Tomoyuki
    Hashimoto, Daigo
    Teshima, Takanori
    ANNALS OF HEMATOLOGY, 2024, : 5333 - 5340
  • [49] Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
    Short, Nicholas J.
    Nguyen, Daniel
    Ravandi, Farhad
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [50] Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells
    Zhao, Linxiang
    Zuo, Shuwei
    Xing, Kun
    Yue, Xiaoshuang
    Zhang, Huimin
    Zhang, Jingyi
    Waxman, Samuel
    Jing, Yongkui
    CANCER RESEARCH, 2024, 84 (06)
12345